Cyprus Mail
BusinessHealthcareInternational

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

astrazenneca

AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

Follow the Cyprus Mail on Google News

Related Posts

‘Cyprus is a reliable business centre’

Tom Cleaver

Guidelines for logo size: What is the best logo size for social media and websites?

CM Guest Columnist

Verbex Group Review: 5 trading tips for first-time Forex Traders [verbexg.com]

CM Guest Columnist

Cyprus Business Now

Kyriacos Nicolaou

Tesla’s plan for affordable cars takes page from Detroit rivals

Reuters News Service

War and peace on the brink

Ioannis Tirkides